Home > News > Advectus and Immune Announce Nano-Pharmaceutical Project Update
September 4th, 2003
Advectus and Immune Announce Nano-Pharmaceutical Project Update
Advectus Life Sciences Inc. announced today that it has acquired an option from Immune Network Ltd. which, if exercised, would give the Company an exclusive worldwide interest in a new nanotechnology-based formulation for the treatment of Alzheimer's disease based on compositions that penetrate the "blood-brain barrier" with existing drugs.
Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014
Journal Nanotechnology Progress International (JONPI), 2014, Volume 5, Issue 1, pp 1-24 October 22nd, 2014
TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014
‘Designer’ nanodevice could improve treatment options for cancer sufferers October 22nd, 2014